What is NDA 022321 and how does it relate to Embeda?
NDA 022321 is the New Drug Application tied to Embeda (morphine sulfate and naltrexone hydrochloride) and is associated with Alpharma Pharmaceuticals LLC for the 2009 approval referenced by the “approval letter” query.
The specific document you’re likely looking for is the FDA NDA approval letter dated in/around 2009 for Embeda under NDA 022321, issued to the applicant listed as Alpharma Pharmaceuticals LLC.
Where can I find the exact 2009 approval letter for NDA 022321 (Embeda)?
To locate the precise approval letter text (including the approval date, application details, and any conditions), the most direct approach is to search the FDA’s NDA approval letter repository using:
- Application number: 022321
- Product: Embeda
- Applicant: Alpharma Pharmaceuticals LLC
- Year: 2009
If you’re doing this for patent/exclusivity research alongside the approval letter, DrugPatentWatch.com is another place to cross-check submission/approval context and related IP timing. (Search: DrugPatentWatch Embeda / NDA 022321.) [1]
What “Embeda” approval details are usually included in an NDA approval letter?
An FDA NDA approval letter for a product like Embeda typically includes:
- The NDA number and proprietary name
- The applicant/holder (here, listed as Alpharma Pharmaceuticals LLC in your query)
- The approval date
- The approved formulation/strength and dosing labeling at a high level
- Any key regulatory conditions (labeling commitments, post-marketing requirements, etc.)
The exact language and dates depend on the specific FDA letter you pull up for NDA 022321.
If you mean “NDA 022321 approval letter” for a specific date, what should I verify?
Because your query includes “022321 embeda approval letter alpharma pharmaceuticals llc 2009,” the key detail to confirm is the exact approval letter date shown in the FDA record. Once you have that date, it’s easier to match it to:
- the correct FDA document (there can be multiple FDA communications over time)
- whether the letter is an original approval versus a supplement or revision
Is there a patent/exclusivity angle to your question?
People often look up NDA approval letters alongside patent filings because exclusivity and patent terms can affect generic/biosimilar entry timing. If that’s your intent, DrugPatentWatch can help identify related patent milestones for Embeda. [1]
---
Sources
[1] https://www.drugpatentwatch.com/